Divalproex-ER pharmacokinetics in older children and adolescents

Sandeep Dutta, Yiming Zhang, Jeannine M. Conway, Floyd R. Sallee, Victor Biton, Michael D. Reed, Gregory L. Kearns

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Valproic acid pharmacokinetic profile and tolerability after administration of divalproex sodium extended-release tablets was characterized in older children and adolescents. In this multiple-dose, open-label, pharmacokinetic study, the patients were divided into two age groups, 8-11 years (older children; n = 15) and 12-17 years (adolescents; n = 14). Once-daily administration of divalproex sodium extended-release tablets (doses ranged from 250 to 1750 mg) in older children and adolescents produced relatively flat plasma valproic acid concentration-time profiles over the entire 24-hour dosing interval, similar to the pharmacokinetic performance of this formulation in adults. The mean (standard deviation) oral clearance values for unbound valproic acid were 94.3 (51.8) and 82.3 (28.2) mL/h/kg and for total valproic acid were 11.2 (3.77) and 9.06 (2.03) mL/h/kg in older children and adolescents, respectively. Two patients discontinued for administrative reasons, whereas one discontinued for an adverse event (flulike syndrome). Adverse events reported by three or more patients were flu syndrome (5 patients, 17.2%) and headache (3 patients, 10.3%). Reported adverse events were generally mild to moderate in severity and similar to those reported in previous divalproex studies. This study demonstrates that in older children and adolescents, once-daily administration of divalproex sodium extended-release tablets may potentially be used to sustain plasma valproic acid concentrations within the usually accepted therapeutic ranges for various indications.

Original languageEnglish (US)
Pages (from-to)330-337
Number of pages8
JournalPediatric Neurology
Volume30
Issue number5
DOIs
StatePublished - May 1 2004

Fingerprint Dive into the research topics of 'Divalproex-ER pharmacokinetics in older children and adolescents'. Together they form a unique fingerprint.

Cite this